Department of Neurology, Institute of Surgery Research, Daping Hospital, The Third Military Medical University, 10 Changjiang Branch Road, Yuzhong District, Chongqing 400042, China.
J Clin Neurosci. 2012 Oct;19(10):1363-8. doi: 10.1016/j.jocn.2011.10.022. Epub 2012 Aug 20.
Neurothrombectomy is being used increasingly for the treatment of acute ischemic stroke. To assess the recanalization rates and clinical outcomes of patients treated with neurothrombectomy, we searched the CNKI (China National Knowledge Infrastructure), CBM (Chinese Biomedical Literature), MEDLINE and EMBASE databases to 2011 and summarized the outcome data of patients with acute ischemic stroke treated with neurothrombectomy. Forty-six studies (1530 patients) that reported recanalization rates were included in this analysis. Recanalization rates were recorded for the following neurothrombectomy techniques: endovascular thrombectomy (43-100%, median 86%), endovascular thromboaspiration (67-100%, median 83%), laser thrombolysis (41-50%, median 45.5%), and ultrasonification (62-71%, median 66.5%); the respective rates of symptomatic and asymptomatic intracranial hemorrhage were 20%, 22.5%, 12%, and 19% for each of the four types of neurothrombectomy. Clinical outcome data categorized by success or failure in achieving recanalization were available from 12 articles pertaining to 443 patients. At three months, patients in whom recanalization was achieved had better functional outcomes compared to non-recanalized patients (odds ratio [OR], 5.58; 95% confidence interval [CI], 2.98-10.45). In addition, the three-month mortality was lower in recanalized patients (OR, 0.37; 95% CI, 0.24-0.57). Among the various treatments for acute ischemic stroke, neurothrombectomy appears the most promising. Neurothrombectomy devices show great potential in improving functional outcomes and reducing mortality in patients with acute ischemic stroke, and meta-analysis confirms that successful recanalization was the most important indicator of predicting clinical benefit.
神经血管内血栓切除术越来越多地用于治疗急性缺血性脑卒中。为了评估接受神经血管内血栓切除术治疗的患者的再通率和临床结局,我们检索了中国知网(CNKI)、中国生物医学文献数据库(CBM)、MEDLINE 和 EMBASE 数据库,截至 2011 年,总结了接受神经血管内血栓切除术治疗的急性缺血性脑卒中患者的结局数据。本分析纳入了 46 项(共 1530 例患者)报道再通率的研究。纳入的神经血管内血栓切除术技术包括血管内血栓切除术(43%-100%,中位数 86%)、血管内血栓抽吸术(67%-100%,中位数 83%)、激光溶栓(41%-50%,中位数 45.5%)和超声溶栓(62%-71%,中位数 66.5%);四种类型的神经血管内血栓切除术的症状性和无症状性颅内出血的发生率分别为 20%、22.5%、12%和 19%。12 篇文章(共 443 例患者)提供了根据再通成功与否进行分类的临床结局数据。在 3 个月时,与未再通患者相比,再通成功的患者功能结局更好(比值比 [OR],5.58;95%置信区间 [CI],2.98-10.45)。此外,再通患者的 3 个月死亡率较低(OR,0.37;95% CI,0.24-0.57)。在急性缺血性脑卒中的各种治疗方法中,神经血管内血栓切除术似乎最有前途。神经血管内血栓切除术器械在改善急性缺血性脑卒中患者的功能结局和降低死亡率方面具有巨大潜力,荟萃分析证实,成功再通是预测临床获益的最重要指标。